Treatment of lung cancer
256 results
101 - 200
Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE- Psychosocial interventions for reducing fatigue during cancer treatment in adults
- Palliative endobronchial brachytherapy for non‐small cell lung cancer
- Concurrent chemoradiotherapy in non-small cell lung cancer: Cochrane systematic review
- PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
- Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults
Breast cancer - Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer: Cochrane systematic review
- Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
- Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer: Cochrane systematic review
Daily multivitamins have minimal, if any, effect on preventing cancer in men and do not affect mortality- Gefitinib for advanced non-small cell lung cancer: Cochrane systematic review
- Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases: Cochrane systematic review
- Intermittent versus continuous androgen suppression for prostatic cancer
- Chemotherapy for brain metastases from small cell lung cancer: Cochrane systematic review
- Antibody induction therapy for lung transplant recipients
- Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
- Biomedical risk assessment as an aid for smoking cessation
- Prolonged cough in adults
- Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): Cochrane systematic review
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
- PSA screening has marginal effect on mortality in European study (ERSPC)
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer: Cochrane systematic review
- Management of adverse effects of radiotherapy
- Vitamins E and C and selenium do not reduce risk of prostate or total cancer in men
- Short term benefits for laparoscopic colorectal resection
- Anticoagulation for perioperative thromboprophylaxis in people with cancer
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
- Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy: Cochrane systematic review
- Organ transplant recipient in primary health care
- Pharmacological treatments for fatigue associated with palliative care: Cochrane systematic review
- Anticoagulation for the initial treatment of venous thromboembolism in people with cancer
- USPSTF review of the benefits and harms of menopausal hormone therapy
- Guidelines for end of life care (ACP)
- Platinum versus non‐platinum chemotherapy regimens for small cell lung cancer
- Cannabis‐based medicines and medical cannabis for adults with cancer pain
- Lymphangitis
- Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
- Interventions for the management of malignant pleural effusions: a network meta‐analysis
- Carotenoids and omega-3 fatty acids do not reduce risk of advanced AMD
- Second‐line chemotherapy for non‐small cell lung cancer
- Semuloparin reduces VTE in cancer patients but at high cost (SAVE-ONCO)
- Haemoptysis
- Radiotherapy for early breast cancer: Cochrane systematic review
- Platinum‐containing regimens for triple‐negative metastatic breast cancer
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
- Anaesthetic techniques for risk of malignant tumour recurrence
- Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
- Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
- Alemtuzumab for patients with chronic lymphocytic leukaemia: Cochrane systematic review
- Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients
- Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults: Cochrane systematic review
- Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases: Cochrane systematic review
- Antidepressants for depression in medical illness: Cochrane systematic review
- Chemotherapy for advanced non‐small cell lung cancer in the elderly population
- Chemotherapy versus best supportive care for extensive small cell lung cancer: Cochrane systematic review
- Adverse effects of antineoplastic agents
- Percutaneous ethanol injection for liver metastases
- Impact of PSA screening on quality of life
- Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under: Cochrane systematic review
- Telephone interventions for symptom management in adults with cancer
- Immunotherapy for advanced renal cell cancer: Cochrane systematic review
- Cyclophosphamide for connective tissue disease–associated interstitial lung disease
- Fewer overall hospital days with use of indwelling pleural catheters vs pleurodesis for malignant effusions
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer
- Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
- Platinum‐containing regimens for metastatic breast cancer
- Palliative treatment
- Mindfulness‐based stress reduction for women diagnosed with breast cancer
- Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis
- Population screening for cancer
- Alcoholic liver disease (ALD)
- PET‐CT for assessing mediastinal lymph node involvement in patients with suspected resectable non‐small cell lung cancer
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma
- Topical tretinoin may increase all-cause mortality
- Pneumonia
- Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
- Golimumab for rheumatoid arthritis
- Interventions for fatigue and weight loss in adults with advanced progressive illness
- Genetic test results that identify increased risk do not change behavior
- Antifibrinolytic therapy to reduce haemoptysis from any cause
- Fluorine‐18‐fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma
- PSA for screening of prostate cancer
- Lymphomas
- Targeted therapy for advanced renal cell carcinoma
- Antitubercular medication in ambulatory care
- Unintentional weight loss in adults